FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 891 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab July 22, 2024 Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity... December 5, 2022 The Cancer Moonshot: A Midpoint Progress Update January 11, 2021 TILs Therapy Shows Promise in the Management of Anti-PD-1-Resistant Metastatic NSCLC August 23, 2021 Load more HOT NEWS Combination Chemo Helps People with Leiomyosarcoma Live Longer Transforming Cancer Clinical Trials for Better, Faster Results ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΕΟΥΣ Long-Term Follow-Up Confirms a Sustained Reduction in Deaths from Prostate Cancer...
